Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels

[...]the observed outcome in our omalizumab trial might not entirely reflect drug-associated clinical changes. [...]only a very small proportion (probably between 1% and 5 % of all serum IgE molecules) in our patients was bound by omalizumab.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of allergy and clinical immunology 2007-11, Vol.120 (5), p.1223-1225
Hauptverfasser:	Belloni, Benedetta, MD, Ziai, Mahzad, MD, Lim, Annick, MS, Lemercier, Brigitte, BS, Sbornik, Martin, MD, Weidinger, Stephan, MD, Andres, Christian, MD, Schnopp, Christina, MD, Ring, Johannes, MD, Hein, Rüdiger, MD, Ollert, Markus, MD, Mempel, Martin, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Allergy and Immunology Anti-Allergic Agents - administration & dosage Anti-Allergic Agents - pharmacology Anti-Allergic Agents - therapeutic use Antibodies, Anti-Idiotypic - administration & dosage Antibodies, Anti-Idiotypic - therapeutic use Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Dermatitis, Atopic - drug therapy Drug dosages Eczema Female Humans Immunoglobulin E - blood Immunoglobulin E - drug effects Immunoglobulin E - genetics Immunoglobulins Male Middle Aged Omalizumab Patients Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	[...]the observed outcome in our omalizumab trial might not entirely reflect drug-associated clinical changes. [...]only a very small proportion (probably between 1% and 5 % of all serum IgE molecules) in our patients was bound by omalizumab.
ISSN:	0091-6749 1097-6825
DOI:	10.1016/j.jaci.2007.08.060